0.1399
price up icon5.27%   0.007
pre-market  Vorhandelsmarkt:  .14   0.0001   +0.07%
loading
Schlusskurs vom Vortag:
$0.1329
Offen:
$0.1346
24-Stunden-Volumen:
2.32M
Relative Volume:
2.37
Marktkapitalisierung:
$5.01M
Einnahmen:
$7.10M
Nettoeinkommen (Verlust:
$-39.43M
KGV:
-0.1488
EPS:
-0.94
Netto-Cashflow:
$-46.50M
1W Leistung:
+17.86%
1M Leistung:
-57.59%
6M Leistung:
-76.09%
1J Leistung:
-80.07%
1-Tages-Spanne:
Value
$0.128
$0.14
1-Wochen-Bereich:
Value
$0.1151
$0.14
52-Wochen-Spanne:
Value
$0.11
$0.87

Spruce Biosciences Inc Stock (SPRB) Company Profile

Name
Firmenname
Spruce Biosciences Inc
Name
Telefon
(415) 655-4168
Name
Adresse
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Name
Mitarbeiter
21
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
SPRB's Discussions on Twitter

Vergleichen Sie SPRB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SPRB
Spruce Biosciences Inc
0.1399 5.01M 7.10M -39.43M -46.50M -0.94
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.47 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.76 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.51 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.61 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.16 24.89B 3.81B -644.79M -669.77M -6.24

Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-11 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2024-12-11 Herabstufung Oppenheimer Outperform → Perform
2024-03-14 Herabstufung Guggenheim Buy → Neutral
2024-03-14 Herabstufung H.C. Wainwright Buy → Neutral
2024-03-14 Herabstufung Ladenburg Thalmann Buy → Neutral
2024-03-14 Herabstufung Leerink Partners Outperform → Market Perform
2024-03-14 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2024-02-21 Eingeleitet Guggenheim Buy
2021-12-17 Eingeleitet Oppenheimer Outperform
2021-12-10 Eingeleitet The Benchmark Company Speculative Buy
2021-11-16 Herabstufung SVB Leerink Outperform → Mkt Perform
2021-07-19 Eingeleitet H.C. Wainwright Buy
2021-04-26 Fortgesetzt Credit Suisse Outperform
2020-11-03 Eingeleitet Cowen Outperform
2020-11-03 Eingeleitet Credit Suisse Outperform
2020-11-03 Eingeleitet RBC Capital Mkts Outperform
2020-11-03 Eingeleitet SVB Leerink Outperform
Alle ansehen

Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten

pulisher
Apr 24, 2025

Citizens JMP maintains Market Perform on Spruce Biosciences By Investing.com - Investing.com Nigeria

Apr 24, 2025
pulisher
Apr 23, 2025

Citizens JMP maintains Market Perform on Spruce Biosciences - Investing.com

Apr 23, 2025
pulisher
Apr 22, 2025

The Potential Rise in the Price of Spruce Biosciences Inc (SPRB) following insiders activity - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

TD Cowen reiterates NextDecade Corporation (NEXT) stock to a Buy - knoxdaily.com

Apr 22, 2025
pulisher
Apr 19, 2025

Q1 Earnings Forecast for SPRB Issued By Leerink Partnrs - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $2.17 Consensus Target Price from Analysts - Defense World

Apr 19, 2025
pulisher
Apr 17, 2025

Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript - Insider Monkey

Apr 17, 2025
pulisher
Apr 17, 2025

Spruce Biosciences Inc (NASDAQ: SPRB) Slashes -6.82%: What Could Be On The Way Going Forward? - stocksregister.com

Apr 17, 2025
pulisher
Apr 17, 2025

Spruce Bio sows the seeds of its new future - Pharmaphorum

Apr 17, 2025
pulisher
Apr 17, 2025

Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com

Apr 17, 2025
pulisher
Apr 16, 2025

Spruce Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 16, 2025
pulisher
Apr 16, 2025

RBC Cuts Price Target on Spruce Biosciences to $0.50 From $1.50, Keeps Sector Perform, Speculative Risk - marketscreener.com

Apr 16, 2025
pulisher
Apr 16, 2025

Spruce Biosciences Announces New Corporate Strategy and Acquisit - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

SPRB stock touches 52-week low at $0.18 amid market challenges By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences plans BLA for rare disease therapy By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals

Apr 15, 2025
pulisher
Apr 15, 2025

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

SPRB stock touches 52-week low at $0.18 amid market challenges - Investing.com Canada

Apr 15, 2025
pulisher
Apr 15, 2025

Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences (SPRB) Acquires New Therapy for Rare Disease Treatment | SPRB Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences plans BLA for rare disease therapy - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

SPRUCE BIOSCIENCES, INC. SEC 10-K Report - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences Announces New Corporate Strategy And Acquisition Of Tralesinidase Alfa - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Major Rare Disease Breakthrough: Spruce Bio Secures Promising Treatment for Fatal Childhood Disease - Stock Titan

Apr 15, 2025
pulisher
Apr 11, 2025

Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace

Apr 11, 2025
pulisher
Apr 08, 2025

Levi & Korsinsky Reminds Shareholders of an Investigation into Spruce Biosciences, Inc. (SPRB) Regarding Potential Securities Fraud Allegations - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 07, 2025

SPRB stock touches 52-week low at $0.26 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

SPRB stock touches 52-week low at $0.26 amid market challenges - Investing.com India

Apr 07, 2025
pulisher
Apr 07, 2025

Congenital Adrenal Hyperplasia Treatment Market: Key Trends, - openPR.com

Apr 07, 2025
pulisher
Apr 01, 2025

Spruce Biosciences reports delayed annual filing By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Spruce Biosciences reports delayed annual filing - Investing.com

Apr 01, 2025
pulisher
Mar 31, 2025

Spruce Biosciences Delays Annual Report Filing - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 31, 2025
pulisher
Mar 25, 2025

Spruce Biosciences stock hits 52-week low at $0.32 - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

In-Depth Analysis Of The Global Congenital Adrenal Hyperplasia Market: Key Drivers, Trends, Growth Opportun... - WhaTech

Mar 25, 2025
pulisher
Mar 25, 2025

Spruce Biosciences stock hits 52-week low at $0.32 By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 22, 2025

SPRUCE BIOSCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 22, 2025
pulisher
Mar 20, 2025

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 20, 2025
pulisher
Mar 14, 2025

Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) PT at $2.38 - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

SPRB Stock Touches 52-Week Low at $0.34 Amid Steep Decline - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 11, 2025

Finanzdaten der Spruce Biosciences Inc-Aktie (SPRB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Spruce Biosciences Inc-Aktie (SPRB) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Charlton Ralph William III
CHIEF MEDICAL OFFICER
Dec 10 '24
Option Exercise
0.00
106,400
0
161,773
Gharib Samir M.
PRESIDENT AND CFO
Dec 16 '24
Option Exercise
0.00
75,750
0
363,841
Gharib Samir M.
PRESIDENT AND CFO
Dec 10 '24
Option Exercise
0.00
154,000
0
356,776
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER
Dec 16 '24
Option Exercise
0.00
200,700
0
506,796
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER
Dec 10 '24
Option Exercise
0.00
358,800
0
466,121
$20.54
price up icon 2.04%
$68.96
price down icon 2.60%
$32.03
price up icon 1.07%
$36.70
price up icon 10.44%
$120.54
price up icon 4.97%
biotechnology ONC
$256.16
price up icon 2.82%
Kapitalisierung:     |  Volumen (24h):